Build Your Own Vaccine Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Build Your Own Vaccine Facility
New modular bioprocessing technology could quicken the response to an outbreak of disease.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 14


Erik Greb
The recent outbreak of cholera in Haiti highlighted the urgent need, most acute in the developing world, for manufacturing capacity that can respond to pandemics rapidly. Modular technology under development by GE Healthcare (Waukesha, WI) and G-Con Manufacturing (College Station, TX) could provide a helpful solution.

The companies are combining GE Healthcare's single-use bioprocessing equipment and G-Con's cleanroom technology to create standard modular bioprocessing facilities (MBFs) that clients could fit with upstream or downstream utilities for their specific applications. If need be, users could refit MBFs with new equipment later without difficulty. Catarina Flyborg, general manager of bioprocess products at GE Healthcare, likens the technology to Legos that users can link to build manufacturing trains.

Each 18 × 25 ft unit could house as much as 2000 L of fermentation capacity. A set of air bearings underneath each MBF will ensure that personnel can physically move the units where they're needed. And, because each of the bioprocessing building blocks will be contained, clients will be able to install them in unclassified spaces.

The MBFs' modularity could help clients quickly set up a small-scale manufacturing facility in any location while requiring fewer capital expenses than building or renovating a facility would entail, says Flyborg. The new technology could make bioprocessing capacity more accessible than before and potentially help respond to emerging health crises quickly.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here